For research use only. Not for therapeutic Use.
Risedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.<br>Risedronate causes a total inhibition of colony formation whereas Etidronate has relatively little effect in calcifying fibroblastic colony-forming unit (CFU-f) cultures of rat bone marrow cells in vitro. Risedronate (1 μM) decreases the formation of colonies displaying osteoblastic characteristics such as alkaline phosphatase expression, collagen accumulation, and calcification. Risedronate (1 nM) and alendronate increases the formation of fibroblastic colonies, suggesting a mild anabolic effect, however, the formation of colonies with osteoblastic properties is not affected.<br>Risedronate (1 mg/kg) significantly increases the volumetric densities of bone (Vb) and osteoblast Vob and decreases Vm more prominently in rats.
| Catalog Number | A000751 |
| CAS Number | 115436-72-1 |
| Synonyms | NE 58095 Sodium |
| Molecular Formula | C7H10NO7P2 • Na |
| Purity | ≥95% |
| Storage | 3 years -20C powder |
| InChIKey | DRFDPXKCEWYIAW-UHFFFAOYSA-M |
